1. Innovations in the law on circulation of medicines

Roman Shabrov, managing partner of BRAS Law Firm, head of Research Centre Pharmaceutics and Law, expert at the Center for Research of Regulatory Environment for Pharmaceuticals and Biotechnology, Faculty of Law at Higher School of Economics, Alexey Shadrin, BRAS Law Firm, the Center for Research of Regulatory Environment for Pharmaceuticals and Biotechnology, Faculty of Law at Higher School of Economics.

References

2. Orphan Drug Act//Electronic Code of federal regulation. 316.3
5. Results of the assessment of the drugs availability on the basis of the analysis of consumer prices and pharmaceuticals pricing in the Russian Federation (including a report broken down by constituent entities of the Russian Federation) and in comparable markets of the countries, including those in the CIS, the European Union, and the BRICS. FAS Russia. 2013


20. Expert: 90% of level II documents EEMA has passed today a discussion and assessment of the regulatory impact. URL: http://www.pharmvestnik.ru/publs/lenta/v-rossii/ekspert-nasegodnjashnij-denj-proshli-obsuzhdenie-i-otsenku-regulirujuschego-vozdejstvija-90.html # VinfvnhDIU.